GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Accumulated other comprehensive income (loss)

Nuvation Bio (Nuvation Bio) Accumulated other comprehensive income (loss) : $-1.17 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Nuvation Bio's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was $-1.17 Mil.

Nuvation Bio's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2023 ($-3.30 Mil) to Dec. 2023 ($0.18 Mil) but then declined from Dec. 2023 ($0.18 Mil) to Mar. 2024 ($-1.17 Mil).

Nuvation Bio's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 ($-1.19 Mil) to Dec. 2022 ($-5.53 Mil) but then increased from Dec. 2022 ($-5.53 Mil) to Dec. 2023 ($0.18 Mil).

Nuvation Bio Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Nuvation Bio's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Accumulated other comprehensive income (loss) Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
1.56 -1.19 -5.53 0.18

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.94 -4.40 -3.30 0.18 -1.17

Nuvation Bio Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Nuvation Bio Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
OVID OCUL EYPT VNDA AVIR VIGL XERS ACIU THRD IGMS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
NUVB:USA
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Website
https://www.nuvationbio.com
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).